Moore Capital Management, LP United Therapeutics Corp Transaction History

Moore Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $3.23 Million - $3.88 Million	15,890 Added 21.45%	89,979 $18.8 Million
Q2 2022 Aug 15, 2022	BUY	$174.81 - $241.14 $70,098 - $96,697	401 Added 0.54%	74,089 $17.5 Million
Q1 2022 May 16, 2022	BUY	$166.16 - $213.96 $807,371 - $1.04 Million	4,859 Added 7.06%	73,688 $13.2 Million
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $9.12 Million - $10.7 Million	-49,486 Reduced 41.83%	68,829 $14.9 Million
Q3 2021 Nov 15, 2021	BUY	$179.86 - $214.88 $5.33 Million - $6.37 Million	29,623 Added 33.4%	118,315 $21.8 Million
Q2 2021 Aug 16, 2021	BUY	$170.47 - $211.93 $15.1 Million - $18.8 Million	88,692 New	88,692 $15.9 Million

676

42.1M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.3B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.